Celldex Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Celldex Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 25, 2026, to elect directors, ratify auditors, and approve equity plan amendments.
NASDAQ
Celldex Therapeutics is asking stockholders to approve an amendment to its 2021 Omnibus Equity Incentive Plan, increasing the number of shares available for issuance by 2,000,000 to a total of 9,500,000, plus any unused shares from the 2008 plan.
NASDAQ
Celldex Therapeutics is holding its annual meeting on June 13, 2024, to vote on key proposals including the election of directors, ratification of the auditor, an amendment to the equity incentive plan, and executive compensation.